Cobimetinib, also known as GDC-0973 and XL-518 , is an orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity. MEK inhibitor GDC-0973 specifically binds to and inhibits the catalytic activity of MEK1, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation and activation and decreased tumor cell proliferation. Preclinical studies have demonstrated that this agent is effective in inhibiting the growth of tumor cells bearing a B-RAF mutation, which has been found to be associated with many tumor types.
Fawcett A, Murtaza A, Gregson CHU, Aggarwal VK. Strain-Release-Driven Homologation of Boronic Esters: Application to the Modular Synthesis of Azetidines. J Am Chem Soc. 2019 Mar 20;141(11):4573-4578. doi: 10.1021/jacs.9b01513. Epub 2019 Mar 11. PubMed PMID: 30836746.
Rice KD, Aay N, Anand NK, Blazey CM, Bowles OJ, Bussenius J, Costanzo S, Curtis JK, Defina SC, Dubenko L, Engst S, Joshi AA, Kennedy AR, Kim AI, Koltun ES, Lougheed JC, Manalo JC, Martini JF, Nuss JM, Peto CJ, Tsang TH, Yu P, Johnston S. Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973). ACS Med Chem Lett. 2012 Apr 9;3(5):416-21. doi: 10.1021/ml300049d. eCollection 2012 May 10. PubMed PMID: 24900486; PubMed Central PMCID: PMC4025802.
Naganathan, Sriram; Guz, Nathan; Pfeiffer, Matthew. Preparation of phenylaminophenylhydroxypiperidinylazetidinylmethanone derivatives for use as MEK inhibitors. WO 2014059422. (Assignee Exelixis, Inc., USA)
Li, Chaoping; Cao, Zhihua; Wang, Guangyong; Hu, Peng; Zhou, Zhiguo; Gao, Qiang; Zheng, Baofu. A preparation method of derivative of 3-(piperidin-2-yl)-azetidin-3-ol and application thereof. CN 104725352. (Assignee Shanghai Haoyuan Medchemexpress Co., Ltd., Peop. Rep. China; Shanghai Haoyuan Chemexpress Co., Ltd.)
Xu, Xuenong. Process for the preparation of cobimetinib. WO 2017096996. (Assignee Suzhou Miracpharma Technology Co., Ltd., Peop. Rep. China)
Chen, Jian. Method for synthesizing cobimetinib. CN 106045969. (Assignee Hunan Ouya Biological Co., Ltd., Peop. Rep. China)
Shi, Changqing. Method for synthesizing (S)-3-(piperidine-2-yl)-azetidine-3-ol. CN 106220607. (Assignee Chengdu Baishixing Science and Technology Industry Co., Ltd., Peop. Rep. China)
St. Clair Brown, Adrian. Preparation of crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]-methanone. WO 2017004393. (Assignee Exelixis, Inc., USA)
Shi, Maojian; Zhou, Jinhui; Xu, Zhiqiang; Guan, Hua; Shangguan, Guoqiang. Process for preparation of cobimetinib. CN 106866624. (Assignee Jining Medical University, Peop. Rep. China)
Wu, Xueping; Chen, Yao; Wang, Min. Preparation method of cobimetinib via oxidative coupling cyclization, acylation and addition reaction. Assignee Anqing CHICO Pharmaceutical Co., Ltd., Peop. Rep. China. CN 109232531. 2019.
